The development of this treatment strategy, in contrast to first- and second-generation EGFR-TKIs that act on the central nervous system, has markedly improved both the clinical management and outcome of patients with advanced NSCLC [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.